SUN-LB054 Cilengitide Reverts Thyroid Hormones Effects in Bexarotene Treatment of Breast Cancer Cells

Johanna Díaz Albuja(Consejo Nacional de Investigaciones Científicas y Técnicas), María Díaz Flaqué(Consejo Nacional de Investigaciones Científicas y Técnicas), Graciela Cremaschi(Pontificia Universidad Católica Argentina), Mercedes Debernardi(Consejo Nacional de Investigaciones Científicas y Técnicas), Florencia Cayrol(Cornell University), Cinthia Rosemblit(Consejo Nacional de Investigaciones Científicas y Técnicas)
Journal of the Endocrine Society
April 1, 2019
10.1210/js.2019-sun-lb054
Cited by 1

Related Papers

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
|Nature Communications|2017|108
Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies
|Oncotarget|2018|33
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma
|Molecular Cancer Therapeutics|2022|6
PKCα Activation via the Thyroid Hormone Membrane Receptor Is Key to Thyroid Cancer Growth
|International Journal of Molecular Sciences|2024|1
Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination
|Blood Advances|2025|1